Anixa Biosciences, Inc. today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.”
| Broad coverage extended to Japan and related regions SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.”
Anixa Chairman and CEO Dr. Amit Kumar commented, “This new Japanese patent extends the expanded claims for this novel ovarian cancer vaccine technology to another geographic region, joining the European and U.S. patents awarded last year. As the exclusive worldwide licensee of the technology, we highly value the broad protection this patent provides as our research and development continues. If our vaccine is approved, one of the most aggressive gynecological cancers could be prevented from ever developing in women globally.” The Ovarian Cancer Vaccines patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic. The researchers demonstrated in pre-clinical studies that vaccination against the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED) significantly inhibits tumor growth and enhances overall survival. The results indicate that vaccinating women against AMHR2-ED could provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer. Anixa is the exclusive worldwide licensee for the vaccine technology from Cleveland Clinic, a nonprofit, multispecialty academic medical center. Preclinical work on the vaccine is supported by the National Cancer Institute’s PREVENT Program, a peer-reviewed program designed to support development of the best ideas in cancer prevention. About Anixa Bioscience’s Ovarian Cancer Vaccine About Anixa Biosciences, Inc. Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A - Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:
SOURCE Anixa Biosciences, Inc. | ||
Company Codes: NASDAQ-NMS:ANIX |
View original content to download multimedia:
